Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats

被引：0
|
作者：
Shohei Yamada
Jun Tanabe
Yuji Ogura
Yoshio Nagai
Takeshi Sugaya
Keiichi Ohata
Yasunori Natsuki
Daisuke Ichikawa
Shiika Watanabe
Kazuho Inoue
Seiko Hoshino
Kenjiro Kimura
Yugo Shibagaki
Atsuko Kamijo-Ikemori
机构：
[1] St. Marianna University School of Medicine,Division of Nephrology and Hypertension, Department of Internal Medicine
[2] St. Marianna University School of Medicine,Department of Physiology
[3] St. Marianna University School of Medicine,Division of Metabolism and Endocrinology, Department of Internal Medicine
[4] St. Marianna University School of Medicine,Institute for Ultrastructural Morphology
[5] St. Marianna University School of Medicine,Department of Anatomy
[6] JCHO Tokyo Takanawa Hospital,undefined
来源：
Clinical and Experimental Nephrology | 2021年 / 25卷
关键词：
Diabetes; Diabetic kidney disease (DKD); GLP-1; GLP-1 receptor; Liraglutide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：365 / 375
页数：10
相关论文
共 50 条
  • [11] The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function
    Małgorzata Wajdlich
    Michał Nowicki
    Scientific Reports, 14
  • [12] GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes
    Rojano Toimil, Alba
    Ciudin, Andreea
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (17)
  • [13] Improving management of diabetic kidney disease: will GLP-1 receptor agonists have a role?
    Bellary, Srikanth
    Tahrani, Abd A.
    Barnett, Anthony H.
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (11) : 870 - 871
  • [14] Development of Syringaldehyde as an Agonist of the GLP-1 Receptor to Alleviate Diabetic Disorders in Animal Models
    Lee, Jenpei
    Li, Yingxiao
    Cheng, Juei-Tang
    Liu, I-Min
    Cheng, Kai-Chun
    PHARMACEUTICALS, 2024, 17 (04)
  • [15] Protective effect of GLP-1 analog liraglutide on podocytes in mice with diabetic nephropathy
    Shi, Shaomin
    Chen, Xinghua
    Yu, Wen
    Ke, Xiaolan
    Ma, Tean
    ENDOCRINE CONNECTIONS, 2023, 12 (10)
  • [16] GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
    Kawanami, Daiji
    Takashi, Yuichi
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [17] HEMODYNAMIC EFFECT OF A SINGLE DOSE OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR (GLP-1R) AGONIST LIRAGLUTIDE IN PATIENTS WITH DIABETIC KIDNEY DISEASE
    Wajdlich, M.
    Nowicki, M.
    JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2021, 72 (05): : 751 - 761
  • [18] Renoprotective effects of dulaglutide, a GLP-1 agonist, involving regulation of epithelial-mesenchymal transition in patients with type 2 diabetes and diabetic kidney disease
    Jiang, Daoli
    Meng, Fandong
    Chou, Xiaohua
    Shen, Jiaxin
    Liu, Miaoyan
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2025, : 141 - 153
  • [19] GLP-1 receptor agonist-induced diabetic ketoacidosis: A case report
    Zhang, Jiaming
    Ma, Ying
    Zu, Qianhe
    Wang, Xiaohui
    Zhang, Yao
    MEDICINE, 2024, 103 (39) : e39799
  • [20] GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side
    Dieter, Brad P.
    Alicic, Radica Z.
    Tuttle, Katherine R.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2018, 315 (06) : F1519 - F1525
12345